Optimizing Treatment for Patients With Diabetes Mellitus: Glycemic and Nonglycemic Effects
The Journal of The American Osteopathic Association
Category:
You are here
Home » Tags » DPP-4 inhibitors
DPP-4 inhibitors
Here We Go Again: Another New Therapy For Type 2 Diabetes
Posted January 17, 2013 by John L. Leahy, MD(Full disclosure – I am an Advisor to Janssen pharmaceuticals that makes canagliflozin)
An FDA advisory panel last week reviewed canagliflozin, with the majority recommending approval. Canaglifozin is the first member of a new class of oral medications for type 2 diabetes–sodium-glucose co-transportor-2 (SGLT2) inhibitors–that will likely make it to the U.S. market.
Year in Diabetes 2012: The Diabetes Tsunami
R. Sherwin and A. M. Jastreboff
Journal of Clinical Endocrinology and Metabolism
Category:
Who is the Right Patient for SGLT-2 Inhibitors?
Posted January 17, 2013 by Irl B. Hirsch, MDDr. Leahy’s comments are right-on target. Some further observations by another endocrinologist who can’t determine who the best patient for this new class of drugs will be:
1. The advisory committee had problems with the bump in LDL-cholesterol. True, this is a surrogate, not a true “outcome” that will be determined in the CANVAS study. But do you recall the last time we had this debate with a diabetes drug?
Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.
DeVries, J Hans; Bain, Stephen C; Rodbard, Helena W; Seufert, Jochen; D'Alessio, David; Thomsen, Anne B; Zychma, Marcin; Rosenstock, Julio
Diabetes care; 2012 Jul;35(7):1446-54. PMID: 22584132
Category:
Podcast: A Discussion About 2012 ADA/EASD Position Statement
Posted August 2, 2012 by Doron Schneider, MD, FACPTags: